Mission

High quality clinical and public health research in infectious disease for Singapore and regionally.

Vision

1. ​​ To foster research collaboration in infectious disease and microbiology among public healthcare and academic institutions.
2. To be a sustainable infrastructure to support clinician-investigators to perform clinically relevant and practice-oriented research that addresses controversies in treatment, and participate in large multinational studies.
3. To further public knowledge of infectious diseases via implementation research.
4. To be always ready to support outbreak research of national importance.
   

SCRN is overseen by an executive committee with representative from every public hospital in Singapore to engage local infectious disease physicians, microbiologists and scientists in a collaborative approach to spearhead cross-institutional clinical research in Singapore. In addition, head of SCRN leads a team that supports SCRN with administrative matters and coordinate clinical studies. It comprises research fellows, manager, executive, and a team of clinical research coordinators who are certified in Good Clinical Practice (GCP).

		​
​Associate Professor Barnaby Young ​Senior Consultant, Department of Infectious Diseases, NCID  (Head of SCRN)​	​Assistant Professor Shirin Kalimuddin​​ Senior Consultant, Department of Infectious Diseases, SG​​​H	Professor David Lye Chien Boon​ ​Senior Consultant, Department of Infectious Diseases, NCID​​
​		​
​Associate Professor Yi Ann Louis Chai Senior Consultant, Division of Infectious Diseases, NUH	​Dr Li Jia Hui Head and Consultant, Infectious Diseases, KKH​	Dr Tan Seow Yen Consultant, Department of Infectious Diseases, CGH​
​	​	​​
Dr Louisa Sun Consultant, Infectious Diseases, AH​	Dr Ooi Say Tat​ Senior Consultant, Division of Infectious Diseases, KTPH​​​	​Adjunct Assistant Professor Surinder Kaur M S Pada​ Head of Division & Senior Consultant, Division of Infectious Diseases, NTFGH​​
Dr Zheng Shu Wei Consultant, Department of Infectious Disease, SKH	Dr Ray Lin Junhao Head and Consultant, Infectious Diseases, WH	​ ​

​

SCRN partners include:

​​

​As of December 2023, SCRN has received $24.6M to facilitate 68 studies which enrolled over 7,800 participants. 

Singapore's first human challenge study 'The Singapore Platform for Controlled Human Infections with SARS-CoV-2', also known as Sing-CoV, aims to conduct a safe SARS-CoV-2 Delta variant human infection challenge in adult volunteers to investigate factors associated with susceptibility to and protection from infection, and to facilitate the development of vaccines, antivirals, and other interventions.​

Study objectives are:

• Establish a SARS-CoV-2 controlled human infection (CHI) model in previously vaccinated, seropositive volunteers in Singapore, with an infection rate of up to 70%.
• Characterise the clinical, virological and immunological responses following controlled inoculation of Delta variant SARS-CoV-2 in Singapore volunteers.
• Identify determinants of breakthrough infection and correlates of protection in individuals with pre-existing immunity.
• Explore antigenic imprinting and the effects of pre-existing immunity on response to infection with an immune escape variant.
• Examine time-course of the generation of respiratory aerosols containing infectious virus from inoculation onwards. 

Recruitment starts in June-2024.

If you are interested to participate in the study and would like to speak to a study team member, please email us at scrn@ncid.s​g.

International adaptive platform trial 'Staphylococcus aureus Network Adaptive Platform' also known as SNAP, aims to find out which of the antibiotics currently in use work best to treat patients with Staphylococcus aureus bacteraemia (SAB).

SAB is a common and severe bloodstream infection with a 90-day mortality of 15-30% despite current best available therapies. Staphylococcus aureus is a type of bacteria that can grouped into three types depending on their antibiotic sensitivity profile: penicillin-susceptible S. aureus (PSSA), methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA). The objective of SNAP is to identify the effect of a range of clinical interventions on all-cause 90-day mortality.

This study is currently recruiting.

For further information on SNAP trial, please click here.

If you are interested to participate in the study and would like to speak to a study team member, please email us at scrn@ncid.s​g.​

​International, multicentre, randomised controlled trial- ‘Early oral step-down antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia’, also known as INVEST, aims to determine whether oral antibiotics are as effective and safe compared with intravenous antibiotics in treating uncomplicated bloodstream infections by Gram-negative bacteria.

The incidence of Gram-negative bacteraemia is rising globally, and remains a major cause of morbidity and mortality for hospitalised patients. Although practice guidelines provide general recommendations for treatment duration for Gram-negative bacteraemia, the optimal route of administration is yet to be definitively defined. The majority of patients with Gram-negative bacteraemia initially receive intravenous (IV) antibiotic therapy. Compared with IV therapy, oral therapy eliminates the risk of catheter-associated adverse events, enhances patient quality of life, and reduces total healthcare costs.

This study is currently recruiting.

If you are interested to participate in the study and would like to speak to a study team member, please email us at scrn@ncid.s​g.

Multicentre, observational prospective study ‘Infectious Diseases Consortium for Study on Integrated and Innovative Approaches for Management of Respiratory Infections: Respiratory Infections Research and Outcome study’, also known as I3D-RESPIRO, aims to evaluate the causes and outcomes of moderate-to-severe Community Acquired Pneumonia in Singapore and the surrounding region, so as to facilitate development of new strategies to diagnose and treat them​.